Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAPCA: Relugolix and Enzalutamide in High-risk Locally Advanced Prostate Cancer
NCT06130995Phase 1Recruiting
- Sponsor
- University of Oklahoma
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tissue-plasminogen activator and enzalutamide in prostate cancer (PCa), sponsored by University of Oklahoma. Primary endpoints: Dose Limiting Toxicity and Pathologic Complete Response and Minimal Residual Disease. Started Dec 2024; status: recruiting.
02
Drugs
tissue-plasminogen activatorenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06130995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130995.